百济神州首次实现全年盈利,明星产品贡献超七成营收,近五年研发投入超630亿元

红星资本局
Apr 16

红星资本局4月16日消息,成立16年的A股创新药龙头百济神州(688235.SH;6160.HK),在2025年度正式盈利。  4月14日晚,百济神州发布2025年年报,全年实现营业收入382.25亿元,同比增长40.46%;实现归母净利润14.61亿元,实现扭亏为盈,2024年同期公司亏损49.78亿元。  红星资本局注意到,百济神州的盈利,主要靠抗肿瘤类药物。其中,明星药物百悦泽2025年全球...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10